Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue

On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.’s GH Shield blood test for colorectal cancer (CRC) screening.The U.S. Food and Drug Administration (FDA) approved Shield in July 2024 as the first blood test for primary CRC screening.Medicare already covers the test.For Medicare patients beginning April 1, the Shield test will be reimbursed at $1,495 during the initial nine-month ADLT period.Also Read: What ...